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ABSTRACT
The emergence of less common but medically important fungal pathogens contributes to the rate of
morbidity and mortality, especially in the increasingly expanding population of immunocompromised
patients. These pathogens include septate ﬁlamentous fungi (e.g., Fusarium spp., Scedosporium spp.,
Trichoderma spp.), nonseptate Zygomycetes, the endemic dimorphic pathogen Penicillium marneffei, and
non-Cryptococcus, non-Candida pathogenic yeast (e.g., Trichosporon spp.). The medical community is thus
called upon to acquire an understanding of the microbiology, epidemiology and pathogenesis of these
previously uncommon pathogens in order to become familiar with the options for prevention and
treatment.
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INTRODUCTION
Candida spp. constitute the third to fourth most
common causes of nosocomial bloodstream infec-
tion. Aspergillus spp. is the most common cause of
infectious pneumonic mortality in haematopoietic
transplant recipients. Cryptococcus neoformans is
the most common cause of fungal-related mortal-
ity in human immunodeﬁciency virus (HIV)-
infected patients. Although these organisms are
important pathogens, less common but emerging
fungal pathogens also cause morbidity and mor-
tality in an increasingly expanding immunocom-
promised patient population.
These emerging pathogens include septate ﬁl-
amentous fungi (Fusarium spp., Scedosporium spp.,
Trichoderma spp. and various dematiaceous
moulds), an expanding group of nonseptate
Zygomycetes, the endemic dimorphic pathogen
Penicillium marneffei and non-Cryptococcus, non-
Candida pathogenic yeasts such as Trichosporon
species [1–3].
The increasing importance of these isolates
as causes of life-threatening invasive fungal
infections in the transplant recipient requires
familiarity with the microbiology, epidemiology,
pathogenesis and options for the prevention and
treatment of these previously uncommon oppor-
tunistic pathogens. We will therefore brieﬂy
review the microbiology, pathogenesis, epidemi-
ology, clinical manifestations, diagnosis and treat-
ment of these organisms.
FILAMENTOUS FUNGI
Hyaline septate moulds (agents
of hyalohyphomycosis)
‘Hyalohyphomycosis’ is the term used to repre-
sent infections caused by colourless septate fungal
hyphae in infected tissue. In tissue they appear as
hyaline (lightly or nonpigmented), septate,
branching ﬁlamentous organisms that can mimic
aspergillosis. Deﬁnitive identiﬁcation in hyalo-
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hyphomycosis requires isolation of the fungal
organism; they may be misidentiﬁed as Aspergil-
lus spp. in routine histological sections. Hyaline
septate moulds are identiﬁed in culture by their
macroscopic and microscopic morphology with
differences in conidiogenesis.
Fusarium spp.
Microbiology. Fusarium spp. are hyaline ﬁlamen-
tous fungi that produce microconidia and macro-
conidia. In the early phase of growth where only
microconidia are apparent, some Fusarium spp.
may resemble Acremonium spp. In the later phases
of growth, the more characteristic canoe-shaped
or plantain-shaped macroconidia are used in
identifying the genus and species of Fusarium.
F. solani, F. oxysporum and F. moniliforme are the
most common species.
Epidemiology. Fusarium spp. have become increas-
ingly recognized as a cause of invasive fungal
infections in neutropenic patients and in those
undergoing transplantation [3–11]. Some centres
have reported Fusarium to be second only to
Aspergillus as the cause of life-threatening ﬁla-
mentous fungal infection in their transplant
patients [3,4]. Fusarium species have long been
associated with infections of the skin, nail and
cornea but they seldom cause locally invasive
disease in the immunocompetent patient [5,6].
Found in soil, water and decaying material,
Fusarium spp. are well-known plant pathogens
that may cause extensive crop destruction and
contamination. Risk factors for invasive fusariosis
include persistent neutropenia and graft-versus-
host disease (GVHD), particularly the latter. The
patient population with GVHD is particularly at
risk in the setting of cord blood transplantation,
matched unrelated donors and use of high-dose
corticosteroids.
Pathogenesis. Inhalation of the conidia of Fusarium
through the lung and paranasal sinuses after
transplantation or intensive chemotherapy may
lead to sinopulmonary infection with angioinva-
sion and infarction or progress to disseminated
disease. Secondary disruption of skin integrity
appears to be a relatively common portal of entry
for disseminated infection with Fusarium in the
immunocompromised host. This may occur after
local trauma to the skin, after placement of
vascular catheters, or in the setting of onychomy-
cosis with associated cellulitis where Fusarium spp.
are known pathogens. The most striking clinical
manifestation of this propensity for local cutane-
ous invasion is observed in neutropenic patients
with Fusarium paronychia of the great toe. As
Fusarium spp. are a cause of positive blood cultures
and nodular cutaneous lesions, Liu et al. have
suggested that the pathogenesis of this dissemi-
nation may be, in part, the result of ‘adventitious
forms’ or microconidia that occur in-vivo [12].
Clinical manifestations. Invasive fusariosis most
commonly presents as fever and pulmonary
inﬁltrates and ⁄ or sinusitis. In comparisons to
invasive aspergillosis, disseminated fusariosis
presents commonly with nodular cutaneous le-
sions [4,6–9,11]. Disseminated fusariosis is also
associated with a relatively high rate (40–60%) of
recovery from routine blood cultures [9,10].
Diagnosis. Histopathology of invasive fusariosis
reveals branching septate hyphae that are difﬁcult
to distinguish from Aspergillus spp. and other
hyaline moulds [13]. Thus, deﬁnitive diagnosis
relies on examination of cultures. In culture,
Fusarium spp. are characterised by canoe-shaped
or banana-shaped macroconidia. Deﬁnitive diag-
nosis to the species level may require referral of
the culture to a mycology reference laboratory.
Unfortunately, the most common early presenta-
tion of infection in neutropenic hosts is fever
alone without clinical signs of infection or pos-
itive culture. Recent studies using polymerase
chain reaction techniques of blood and broncho-
alveolar lavage samples hold promise for earlier
diagnosis in patients at risk for invasive mould
infections in the future.
Treatment and outcome. The outcome for dissem-
inated fusariosis in neutropenic patients and
transplant recipients remains extremely poor.
Response rates vary but mortality rates as high
as 100% have been reported in patients who do
not recover from neutropenia [6–15]. Even with
recovery from neutropenia, patients may suffer
progressive fusariosis or develop a chronic infec-
tion similar to that of chronic disseminated
candidiasis. No patient with GVHD responded
to therapy in an earlier MD Anderson Cancer
Center study [9]. Only 25% of patients from the
Fred Hutchinson Cancer Center study responded
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to therapy [4]. Fusarium infections in solid organ
transplant recipients tend to be localised and have
a better overall outcome compared to haemato-
poietic stem cell transplant recipients [15]. Surgi-
cal resection followed by prolonged antifungal
therapy appears to be the most appropriate
treatment for infection in the solid organ trans-
plant recipient.
Fusariosis is commonly ‘resistant’ to ampho-
tericin B [16,17], with breakthrough infections on
empiric therapy with amphotericin B [18]. Suc-
cessful response or disease ‘stabilisation’ has been
reported with higher doses of amphotericin B in
the range of 1.0–1.5 mg ⁄kg or with lipid formu-
lations of amphotericin B, using a dose of at least
5 mg ⁄ kg per day [19–21].
Among the antifungal triazoles, ﬂuconazole and
itraconazole are not active against Fusarium spp.
Current in-vitro and experimental in-vivo data
demonstrate that the new antifungal triazoles,
such as voriconazole and posaconazole, exert
antifungal activity against some Fusarium spp.
[21–26], however they have not been shown to
have fungicidal activity in-vitro. Treatment with
one of the lipid formulations of amphotericin B,
or voriconazole, is recommended as primary
therapy while attempts are made to minimize
the immune deﬁcit with the use of granulocyte
or granulocyte–macrophage colony-stimulating
factor (GCSF or GMCSF) in neutropenic hosts as
well as reducing immune suppressive therapy
when possible.
Scedosporium spp.: S. apiospermum (Pseudallescheria
boydii) and S. proliﬁcans
Microbiology. The genus Scedosporium contains
two medically signiﬁcant species of emerging
fungi, S. apiospermum and S. proliﬁcans (formerly
S. inﬂatum). The teleomorph (sexual state) known
as Pseudallescheria boydii produces dark round
sexual structures (cleistothecia) that contain asci
and ascospores. In the absence of the sexual form
in culture, the organism is identiﬁed as the ana-
morph (asexual form) known as S. apiospermum.
The hyphal forms of S. apiospermum and of
P. boydii in culture appear as branching septate
hyphae that display terminal annelloconidia.
The pyriform terminal conidia may occasionally
be observed in tissue. Otherwise, the genus
Scedosporium in tissue appears as a septate hyaline
mould that resembles Aspergillus species.
The hyphal structures of S. proliﬁcans consist of
dilated or inﬂated phialides along the hyphal
structure that give rise to one or more conidia. The
inﬂated appearance of the phialides of S. proliﬁcans
gave rise to the earlier term for this organism,
‘S. inﬂatum’. The name of the anamorph of this
organism has since been revised on molecular
taxonomic grounds to sexual S. proliﬁcans. The
sexual stage of S. proliﬁcans is a Petriella species.
Epidemiology. S. apiospermum is a saprophytic
mould found in soil, polluted water, sewage,
and manure. S. apiospermum causes three distinct
patterns of infection: mycetoma, deeply invasive
infection and saprophytic involvement [27–36].
S. apiospermum is the most common cause of
mycetoma in North America. Presenting as
tumour-like swelling with draining sinuses, in
the immunocompetent host, S. apiospermum has
been found to be a common isolate in mycetoma
of the lower extremities and less commonly the
hand. Fatal pulmonary and disseminated infec-
tion has been observed in immunocompetent
victims of near-drowning accidents. Deeply inva-
sive infection due to S. apiospermum is most
commonly observed in immunocompromised
patients, with the lungs being the most frequent
site of infection. Nine patients undergoing hae-
matopoietic stem cell transplant at the Fred
Hutchinson Cancer Center were diagnosed with
invasive Scedosporium spp. infections over a
15-year period from 1985 to 1999. S. apiospermum
may also involve the lungs as a saprophytic
process, resulting in the development of a fungus
ball that is radiologically indistinguishable from
aspergilloma. The organism also saprophytically
involves the lower respiratory tract of patients
with cystic ﬁbrosis and broncheictasis.
S. proliﬁcans causes localised infection, usually
restricted to bone and soft tissues, in immuno-
competent patients, and causes deeply invasive
infection in immunocompromised patients.
S. proliﬁcans has been documented to cause
disseminated infections in immunocompromised
patients with neutropenia and after haematopoi-
etic stem cell transplantation [30–35]. A nosoco-
mial outbreak due to S. proliﬁcans was reported
recently in a haematology–oncology unit [36]. The
organism was thought to be aerially transmitted.
Molecular epidemiological analysis conﬁrmed
that the outbreak was caused by a single strain.
In a review of the literature Revankar et al.
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recently reported that 24 of 30 cases of infection
with S. proliﬁcans were reported from Spain or
Australia [37].
Pathogenesis. Phagocytic host defences to conidia
of P. boydii depend upon monocytes and macro-
phages, while defence against hyphae depends
upon peripheral mononuclear lymphocytes.
P. boydii is more susceptible to phagocytic host
defences but is more polyene-resistant than
A. fumigatus [38,39]. S. apiospermum is variably sus-
ceptible to phagocytic function. Selective inhibition
of hyphal damage suggests an important differ-
ence in susceptibility tomyeloperoxidase products
that may be related to the variable pathogenicity
of different isolates of S. apiospermum [39].
The portal of entry of Scedosporium spp. in
immunocompromised patients is thought to be
similar to that of Aspergillus, with inhalation of
conidia leading to sinopulmonary infection and
eventual dissemination to multiple sites including
skin, brain, heart and multiple organs.
Clinical manifestations. Localised infection princi-
pally involving the musculoskeletal system is a
common presentation of scedosporiosis after pen-
etrating trauma in the immunocompetent host.
Mycetoma may ensue to cause destruction of the
muscle, tendons and bone. A chronic infection
with draining sinus tracks is characteristic of
mycetoma. The drainage of Scedosporium myce-
toma contains ‘grains’ that in essence are micro-
colonies of organisms within a matrix of
inﬂammatory debris. Penetrating injury to the
eye may also be complicated by localised Scedos-
porium infection. Sinopulmonary disease is an-
other form of deep localised infection that is
usually present in immunosuppressed hosts.
The respiratory tract is the main portal of entry
of infection by Scedosporium spp. in immunocom-
promised patients. The clinical manifestations of
pulmonary scedosporiosis resemble those of
aspergillosis. Fever is a common manifestation
that should prompt the performance of a compu-
ted tomography scan that may demonstrate a
bronchopneumonia, nodular densities, wedge-
shaped inﬁltrates, or halo sign. In patients recov-
ering from neutropenia, a crescent sign may be
evident. Scedosporium spp. also may saprophyti-
cally involve pre-existing lung cavities to cause a
‘fungus ball’ in patients with tuberculosis or
sarcoidosis.
Disseminated infection is reported for both
species of Scedosporium. Central nervous system
(CNS) infection due to S. apiospermum presents as
focal neurological deﬁcits, including paresis and
seizures. Clinical features of disseminated infec-
tion due to S. proliﬁcans have been characterised
in a recent report from Spain [41]. Fever unre-
sponsive to broad-spectrum antibiotics was the
most common presentation, followed by respira-
tory symptoms (dyspnea and chest pain). Thirty-
seven per cent of the cases developed CNS
symptoms and 25% developed skin lesions char-
acterized by nonpruriginous erythematous, nod-
ular lesions with a necrotic centre in some cases.
Radiological ﬁndings included bilateral focal and
diffuse pulmonary inﬁltrates, single or multiple
nodules and pleural effusions. Other reported
cases and case series have described similar
ﬁndings for S. proliﬁcans [42–45]. In comparison
to Aspergillus spp., there was a relatively high rate
of fungemia, with isolation of the organism in
blood cultures and dissemination to the skin
lesions and central nervous system.
Diagnosis. Deﬁnitive diagnosis of scedosporiosis
depends upon recovery of the organisms from
clinically overt sites of infection. Scedosporium spp.
are seldom contaminants and should be regarded
as pathogenic when recovered from immunocom-
promised patients. Scedosporium spp. may be
recovered from blood cultures. Although the
organisms are indistinguishable histologically in
most instances from Aspergillus species in tissue,
the terminal annelloconidia of S. apiospermum,
when present in tissue, is virtually diagnostic of
the species.
Treatment and outcome. Amphotericin B exhibits
variable in-vitro activity against isolates of
S. apiospermum [38]. Itraconazole and voriconazole
have been shown to be inhibitory but not fungi-
cidal [46,47]. The echinocandins also may have
inhibitory activity in-vitro against S. apiospermum
[48,49]. Administration of high-dose amphotericin
B has been the initial approach to the therapy of
deeply invasive infection with P. boydii, however
the overall response rates have been dismal in
immunocompromised hosts. Treatment with
voriconazole, or one of the other novel broad-
spectrum triazoles still under investigation, may
be more effective; a recent report described six
cases of S. apiospermum (P. boydii) and two cases of
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S. proliﬁcans in paediatric patients who were
treated with voriconazole [27]. The overall res-
ponse of all patients with Scedosporium infection
was 63%. In S. apiospermum infections, 83% had a
successful outcome, however both patients with
S. proliﬁcans infection were refractory to voricon-
azole therapy. In addition to antifungal therapy,
restoration of immune competence is essential for
survival from these frequently fatal infections.
Patients with mycetoma usually require surgery
for control of infection.
Surgical resection remains the only deﬁnitive
therapy for infection by S. proliﬁcans. Medical
therapy of nonresectable or disseminated disease
in immunocompromised patients is ineffective
[42]. S. proliﬁcans is considered to be resistant to
all current antifungal agents including the novel
antifungal triazoles and the echinocandins
[24,46,48]. These in-vitro observations correlate
with the dismal response of S. proliﬁcans infec-
tions to antifungal chemotherapy. Interferon-c
and GM-CSF have been shown to enhance neu-
trophil superoxide production in response to
S. proliﬁcans hyphae in-vitro [49].
Paecilomyces spp.
Microbiology. Paecilomyces is an asexual hyaline
ﬁlamentous fungus related to Penicillium. Paeci-
lomyces has characteristic phialides that distin-
guish this genus from Penicillium spp. There are
two medically important species of the genus
Paecilomyces responsible for human disease:
P. variotii and P. lilacinus. Both species differ
morphologically, clinically and also in their
in-vitro susceptibility to antifungal compounds.
Epidemiology. Paecilomyces spp. are found world-
wide. They are frequently encountered as air-
borne contaminants in clinical specimens and
may be resistant to sterilising techniques. Infec-
tions due to Paecilomyces are uncommon but
devastating events in immunocompromised pa-
tients. There have been numerous reports of
invasive disease in organ and haematopoietic
stem cell transplant patients [50–57], as well as
other immunocompromised patients [58–60]. Sev-
eral outbreaks have been attributed to Paecilomy-
ces in the last two decades. The ﬁrst reported
surgical outbreak reported in 1980 involved 13
cases of P. lilacinus endophthalmitis after inser-
tion of an intraocular lens that was manipulated
with the same neutralizing solution [61]. Two
subsequent outbreaks of P. lilacinus infections
occurred in a haematology–oncology unit after
administration of a contaminated skin lotion
[56].
Pathogenesis. The portal of entry for this organism
is the respiratory tract, indwelling catheters and
the skin, resulting in pneumonitis, fungemia
and disseminated infection. Similar to Fusarium
and Acremonium spp., the development of adven-
titious forms in tissue may explain the propensity
for dissemination [12].
Clinical manifestations. The majority of the human
cases of infections due to Paecilomyces spp. have
been documented in ocular mycoses (mycotic
keratitis and endophthalmitis), and fungal peri-
tonitis in patients undergoing peritoneal dialysis.
Other sites of infections include musculoskeletal,
cutaneous, sinopulmonary, vascular (endocardi-
tis), as well as disseminated disease in immuno-
compromised patients.
Diagnosis. Deﬁnitive diagnosis in most cases rests
upon recovery of the organism and demonstra-
tion of hyphal forms in tissue. Careful mycolog-
ical assessment of the organism is important
because a cursory review may dismiss the organ-
ism in a general clinical microbiology laboratory
as a contaminating Penicillium species.
Treatment and outcome. Because of their different
susceptibilities to antifungal agents, Paecilomyces
should be identiﬁed to the species level. P. variotii
is susceptible to amphotericin B, whereas
P. lilacinus is resistant to amphotericin B and
ﬂucytosine, but demonstrates some susceptibility
to voriconazole and other broad-spectrum triaz-
oles [62–64].
High dosages of conventional deoxycholate
amphotericin B (¼ 1 mg ⁄ kg ⁄day) with surgical
intervention for localised disease have been
recommended as the initial therapy for this
infection. Clinical responses with this strategy,
however, have been poor in previously reported
cases of disseminated disease in immunocompro-
mised patients. The use of alternative agents such
as voriconazole or the high-dose lipid formulation
of amphotericin B (¼ 5 mg ⁄kg ⁄day) for primary
therapy seem to be more reasonable and less toxic
alternatives.
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Trichoderma spp.
Microbiology. Trichoderma is a hyaline mould of
the class Hyphomycetes. Trichoderma spp. are
rapidly growing organisms, the colonies of
which are initially smooth or translucent and
later become ﬂoccose, forming concentric white
and green rings. Trichoderma is characterised
microscopically by smooth-walled, hyaline,
septate and branched hyphae. Five species of the
genus Trichoderma have been identiﬁed as human
pathogens: T. longibrachiatum, T. harzianum,
T. koningii, T. pseudokoningi and T. viride. Among
these species T. longibrachiatum is the most com-
monly recovered from cases of invasive infections.
Epidemiology. Members of the genus Trichoderma
are most commonly recovered from soil, but have
also been isolated from air. Previously regarded
as nonpathogenic to humans, Trichoderma spp.
have emerged as new fungal pathogens in im-
munocompromised patients and peritoneal dialy-
sis patients [64–70]. Fifteen cases of Trichoderma
infections have been previously reported in im-
munocompromised patients. The ﬁrst report des-
cribes a case of T. viride isolated from a
pulmonary mycetoma in a patient with chronic
lung disease [71]. Six cases of peritonitis caused
by different species of Trichoderma were docu-
mented in patients undergoing continuous ambu-
latory peritoneal dialysis [70,72–76]. Only two
patients (infected with T. pseudokoningii and
T. koningii) survived after early catheter removal.
Three cases of disseminated infection by Tricho-
derma were described in two patients receiving
bone marrow transplants (T. pseudokoningii and
T. longibrachiatum) and one in a renal transplant
recipient (T. harzianum) [65].
Pathogenesis. The relative paucity of virulence of
Trichoderma spp. in immunocompetent hosts is
suggested after the report of an inadvertent
infusion of T. viride in a contaminated intravenous
solution. This patient received a single dose of
amphotericin B and remained well [77]. Little is
known, however, about the mechanisms of host
defence against this organism. Whether T. longi-
brachiatum is more virulent compared to other
members of the genus is not known.
Diagnosis. An increased awareness of this uncom-
mon, but frequently fatal, infection should be
considered in immunosuppressed patients with
infections resembling those of Trichoderma. Deﬁn-
itive diagnosis is established by cultures of blood
and ⁄ or other normally sterile tissue or ﬂuids.
Clinical manifestations. Trichoderma infections ap-
pear predominantly in immunocompromised pa-
tients as nodular pulmonary inﬁltrates, peritonitis
(complicating peritoneal dialysis), localised cuta-
neous lesions, and disseminated infection, inclu-
ding CNS infection.
Treatment and outcome. Most isolates of Trichoder-
ma show resistance to ﬂuconazole and 5-ﬂucyto-
sine and are found to be susceptible or
intermediate to amphotericin B, itraconazole,
ketoconazole and miconazole. Recent in-vitro
data indicate that T. longibrachiatum is susceptible
only to relatively high concentrations of ampho-
tericin B [78,79].
Overall mortality associated with disseminated
infections due to Trichoderma spp. approaches
100%. A patient with acute leukaemia and brain
abscess due to T. longibrachiatum was successfully
treated with amphotericin B and surgical drain-
age [80]. Invasive sinusitis in a liver transplant
patient due to T. longibrachiatum was also suc-
cessfully treated with surgery and prolonged
antifungal therapy [81]. A paediatric patient with
aplastic anaemia recovered from a cutaneous
lesion due to T. longibrachiatum with prolonged
antifungal therapy [78]. Favourable outcome of
infections due to Trichoderma spp. was associated
with catheter removal in cases of peritonitis, and
surgical debridement of localized lesions. T. viride
caused a persistent infection of a perihepatic
haematoma in a liver transplant patient who
received amphotericin B and surgical drainage
[82].
Amphotericin B or lipid formulation of amph-
otericin B is used for treatment of patients with
suspected or documented Trichoderma spp. Surgi-
cal resection of localised infection is recom-
mended whenever feasible.
Acremonium spp.
Microbiology. Acremonium spp. (also classiﬁed by
some experts as Cephalosporium spp.) are saproph-
ytic hyaline moulds. Among the Acremonium spp.,
A. stricutm has been reported as one of the
more common causes of infection by this genus.
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Acremonium spp. produce hyphae with character-
istic phialides, and microconidia. The microcon-
idia in early stage of culture may resemble those
of Fusarium spp.
Epidemiology. Acremonium spp. are saprophytic
moulds commonly found in the environment.
Colonisation of humidiﬁer water in the ventilator
system of an ambulatory surgery centre was
thought to be the source of infection for four
cases of endophthalmitis investigated by the
Centers for Disease Control and Prevention.
Many cases of human disease occur in immuno-
competent hosts. Keratomycosis due to Acremo-
nium regularly develops in people who wear
contact lenses. Mycetoma, which is the most
common nonocular infection caused by Acremo-
nium in immunocompetent patients, usually
develops a complication of penetrating trauma.
Invasive disease, however, is almost exclusively
seen in patients with neutropenia, transplanta-
tion, or other immunodeﬁciency [83].
Pathogenesis. The lungs and gastrointestinal tract
are considered portals of entry of deep infection
due to Acremonium spp. Species of Acremonium
produce characteristic hyphae and phialoconidia,
which may be similar to those of Fusarium spp. in
the early stages of growth in-vitro. In a manner
similar to that of Fusarium and Paecilomyces spp.,
Acremonium spp. produce small adventitious uni-
cellular forms in-vivo that may be seen histolog-
ically in the skin and lung tissue of infected
individuals. Production of small adventitious
unicellular forms in-vivo may facilitate dissemin-
ation and may explain the high rate of haematog-
enously disseminated cutaneous lesions, as well
as positive blood cultures observed with these
organisms. Acremonium spp. can invade vascular
structures resulting in thrombosis, tissue infarc-
tion and necrosis. In-vivo sporulation can occur,
resulting in positive blood cultures in cases of
disseminated infections [84].
Diagnosis. Like other hyaline moulds, septate
nonpigmented hyphae are found on routine
histopathologic examination. However, variation
in the diameter of the hyphae and both acute and
right-angle branching are usually present [85].
Nevertheless, the histological features of Acremo-
nium infections are sufﬁciently variable as to
preclude a direct species diagnosis.
Clinical manifestations. The spectrum of invasive
disease includes sinusitis, osteomyelitis, arthritis,
peritonitis, pneumonia and disseminated infec-
tion [86–92].
Treatment. Recent in-vitro studies evaluated the
antifungal activity of currently available antifungals
against Acremonium spp. The species have little
susceptibility to other currently available antifun-
gal agents [89]. Overall, the isolates were relat-
ively resistant to safely achievable concentrations
of the antifungal agents studied. In-vitro antifun-
gal activity was demonstrated with amphotericin
B but not with ﬂuconazole and ﬂucytosine. Given
the infrequency with which this disease occurs,
optimal treatment of invasive infection due to
Acremonium has not been established. Reported
cases of invasive infections, however, suggest some
beneﬁt with the use of amphotericin B and surgical
excision of the infected tissue. Successful treat-
ment of a pulmonary infection due to A. strictum
with posaconazole has recently been reported in
a leukaemic patient who had failed prior treat-
ment with amphotericin B [92], suggesting that
the second-generation triazoles may be effective
agents in treatment of acremonium infections.
Scopulariopsis spp. and Microascus spp.
Microbiology. Scopulariopsis species are hyaline
moulds in anamorphic (asexual) form. Among
the infections due to Scopulariopsis spp., S. brevi-
caulis is the most frequently reported aetioliogic
anamorphic species. Microascus spp. is the teleo-
morphic (sexual) form of another hyaline mould,
which has been associated with deep-seated
infection after transplant [93,94]. M. cinerus and
M. cirrosus are teleomorphs of Scopulariopsis spp.
that have been isolated from deep infection.
Epidemiology. S. brevicaulis has been isolated from
immunocompetent patients with onychomycosis
and localised infections associated with penetrat-
ing traumatic injury. It has also been reported to
cause deeply invasive infection, including sinus-
itis, pulmonary and disseminated infection in
immunocompromised patients [95–98].
Diagnosis. Although multiple skin lesions in a
liver transplant recipient suggested hematogen-
ous spread, this route of dissemination could not
be documented by blood cultures [95]. Diagnosis
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usually depends upon culture of the organism
from tissue containing branching septate hyphae
that are histologically compatible with Scopulari-
opsis spp.
Clinical manifestations. Scopulariopsis infections
cause onychomycosis, localised infections, sinus-
itis, and pulmonary or disseminated infection.
Treatment. There is a paucity of data regarding
in-vitro antifungal susceptibility of Scopulariopsis
spp. and treatment of deeply invasive and dis-
seminated infections caused by these pathogens
[47,62]. For treatment of deep infection, ampho-
tericin B, a lipid formulation of amphotericin B,
itraconazole or voriconazole may be useful ther-
apy. In the reported case of recurrent subcuta-
neous infections due to S. brevicaulis in a liver
transplant recipient, long-term control was
achieved with a combination of surgery and
long-term therapy with terbinaﬁne [95]. As a
result of its pharmacokinetic properties, however,
terbinaﬁne has no efﬁcacy against deep infections.
Response to amphotericin B in either the
anamorph or teleomorph stage has been docu-
mented with either conventional or lipid formu-
lation of amphotericin B. M. cinerus was isolated
from a brain abscess in a patient with GVHD after
allogeneic haematopoietic stem cell transplanta-
tion, and M. cirrosus in a paediatric patient with
cutaneous lesion and consolidating lung inﬁltrate
after autologous stem cell transplant. Both
responded to therapy with lipid formulations of
amphotericin B, with concomitant of surgical
resection and itraconazole for the patient with
the brain abscess [93,94].
Dematiaceous moulds
Microbiology. Dematiaceous fungi constitute a
group of fungal organisms that are characterised
by the presence of pale brown to dark melanin-
like pigment in the cell wall. Clinical entities
associated with dematiaceous fungi are chromo-
blastomycosis and phaeohyphomycosis. Demati-
aceous fungi sometimes are also responsible for
black-grained mycetoma. A detailed description
of superﬁcial localised cutaneous or subcutaneous
infections due to dematiaceous fungi is beyond
the scope of this review. We will focus upon the
deep invasive or disseminated infections caused
by dematiaceous fungi.
The term ‘phaeohyphomycosis’ was introduced
by Ajello et al. [99] in 1974 and means ‘condition
of fungi with dark hyphae’. However, some fungi
produce varying amounts of melanin pigment
in their cell walls under differing conditions.
Moreover, while in-vivo melanin production may
be minimal and fungal elements appear ‘hyaline’,
in culture increasing melanin production leads to
darker pigmentation.
The number of dematiaceous moulds that have
been documented as aetiologic agents of phaeo-
hyphomycosis continues to increase. Several of
these organisms appear to be neurotropic, where
they localise in the CNS causing one or multiple
brain lesions or abscesses. Dematiaceous fungi
known to be neurotropic include Cladophialophora
bantiana, Wangiella (Exophiala) dermatitidis, Ram-
ichloridium obovoideum, Chaetomium atrobrunneum
and Dactylaria (Ochrochonis) gallopavum. Bipolaris
spp. and Exserohilum rostratum most commonly
cause sinusitis and may also invade the CNS via
extension from the paranasal sinuses. Other fun-
gal pathogens known as aetiologic agents of
sinusitis include Alternaria and Curvularia species.
Pathogenesis. Melanin plays an important role in
the evasion of host defence by fungal pathogens,
including dematiaceous moulds. Among the
mechanisms proposed are quenching of oxidative
metabolites, reduced susceptibility to antimicro-
bial peptides, reduced susceptibility to antifungal
compounds, and decreased susceptibility to en-
zymatic degradation [100]. However, because
much of the insight gained from melanin in
fungal pathogenesis is derived from Cryptococcus
neoformans, further investigation of the role of
melanin in host defence in the dematiaceous
moulds and in host defence is warranted [101].
This is particularly important because the biosyn-
thetic pathway of melanin in C. neoformans differs
from that of dematiaceous moulds. Melanin in C.
neoformans is synthesized via the dihydroxyph-
enylalanine (DOPA) pathway, whereas melanin
in dematiaceous moulds such as W. dermatitidis is
synthesized through the dihydroxynaphthalene
polyketide pathway [102].
Epidemiology. Immunocompromised and immu-
nocompetent patients are at risk for development
of CNS phaeohyphomycosis. Immunocompetent
patients may have no history of exposure to a
concentrated source of moulds (e.g. mulch heaps).
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Although most pathogens are distributed world-
wide, there are some distinctive patterns that bear
note. R. obovoideum (R. mackenziei) is a well-known
cause of sinusitis and CNS infection in the Middle
East. This organism should be considered as an
aetiologic agent in patients referred for transplan-
tation from this region of the world and who
manifest signs of sinusitis or CNS infection.
D. gallopava (O. gallopavum) causes an aggressive
CNS infection in immunocompromised patients.
It thrives in high ambient temperatures (¼ 40 C)
and is a well-known cause of epidemic enceph-
alitis in domestic poultry.
Clinical manifestations. The clinical manifestations
of CNS infection by dematiaceous moulds include
headache, fever, and focal neurological deﬁcits.
Immunocompetent patients may have no obvious
pulmonary signs or no dissemination to other
organs.
In the spectrum of sinus infection, sinusitis due
to Bipolaris or Exserohilum may occur in otherwise
healthy patients with nasal polyposis and allergic
rhinitis [103,104]. Such patients often present with
sinus pain or painless proptosis. Sudden blind-
ness can occur as a result of compression of the
optic nerve. Computed tomography or magnetic
resonance imaging usually reveals maxillary and
ethmoid sinus involvement.
Diagnosis. Histological examination of phaeohyp-
homycosis may reveal septate hyphae with irre-
gular diameters and golden brown cell walls.
Early stages of infection may lack this character-
istic pigmentation. Phaeomycotic lesions vary
histologically but may appear as pyogranulomas
with a purulent centre with surrounding lympho-
cytes, monocytes, macrophages and multinucleate
giant cells. By comparison, histopathologic exam-
ination of sinus tissue involved with Bipolaris or
Exserohilum in otherwise healthy patients with
allergic sinusitis demonstrates strands of neu-
trophils and eosinophils with Charcot–Leyden
crystals and scattered septate hyphae. The pig-
mented cell wall of the hyphae in such cases may
be less apparent than in brain abscesses [105].
Culture of infected tissue establishes the deﬁn-
itive microbiological diagnosis. W. (Exophiala)
dermatitidis is recovered in cultures of clinical
specimens as dematiaceous yeast; however, this
organism is dimorphic and develops hyphae in
human tissue.
Treatment and outcome. Cerebral phaeohyphomy-
cosis has a high degree of morbidity andmortality,
requiring early and aggressive therapy. The optimal
medical and surgical treatment has not yet been
established. Historically, early treatment with
amphotericin B and complete surgical excision
has been recommended until newer alternatives
are found. However, the use of voriconazole in
lieu of amphotericin B for CNS phaeohyphomy-
cosis offers a less toxic alternative with oral and
parenteral formulations [106].
As a class, the antifungal triazoles, itraconazole,
voriconazole and posaconazole may have super-
ior activity against many dematiaceous moulds
[107–109]. For management of Bipolaris or Exsero-
hilum in otherwise healthy patients with nasal
polyposis and allergic rhinitis, good surgical
curettage and initial treatment with itraconazole
or voriconazole may be sufﬁcient to eradicate the
infection if there is no intracranial involvement.
Long-term triazole therapy after repeat surgical
therapy may prevent recurrences.
Zygomycetes
Microbiology. The class of Zygomycetes encom-
pass two orders of medically important fungi:
Entomophthorales and the Mucorales. Character-
ised by broad, sparsely septated, and irregularly
branched hyphae in tissue, they appear in culture
as a rapidly growing mould that forms a variety
of structures including stolons, rhizoids, spor-
angia, apophyses, sporangiophores, sporangia,
collumellae and sporangiospores. Rhizopus is the
most common genus to cause infection [110,111],
however a number of other Zygomycetes have
been increasingly reported as causing devastating
infections in immunocompromised patients
[110–121], While a detailed discussion of the class
Zygomycetes is beyond the scope of this paper,
we will review some of the salient features of
these organisms as they infect immunocompro-
mised hosts.
Epidemiology. Zygomycosis develops most fre-
quently in patients with diabetic ketoacidois and
pharmacologically immunocompromised pa-
tients, including those with neutropenia, and
following solid organ or haematopoietic trans-
plantation [110–113]. Patients who are receiving
desferoxamine, such as those with iron or alu-
minium overload states, are also at risk for
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development of zygomycosis. Although the res-
piratory tract is the most common portal of entry
for these pathogens, cutaneous routes of infection
are particularly important in patients in the
setting of surgery, trauma, burns, or neonatal
intensive care. The latter situation occurs as a
result of the tenuous nature of the integument of
newborn infants. The development of zygomyco-
sis in areas of skin breakdown has been associated
with a variety of contaminated adhesive products,
elastic bandages, and tongue depressors used in
the hospital setting.
Pathogenesis. Host defences against zygomycetes
are mediated by monocytes, macrophages and
neutrophils. Pulmonary alveolar macrophages
serve as a ﬁrst line of host defence against
sporangiospores while neutrophils mediate pro-
tection against hyphae. Patients suffer an in-
creased risk for developing zygomycosis as a
result of functional and ⁄ or numerical deﬁciencies
of these cells. The paucity of reports of zygomy-
cosis in HIV-infected patients who do not inject
intravenous illicit drugs indicates that T-cell
dysfunction alone is not a major determinant in
the development of this disease.
Metabolic acidosis is a key factor in predispos-
ing patients to zygomycosis. Low plasma pH
diminishes the phagocytic and chemotactic ability
of neutrophils and decreases the afﬁnity for irol
transferral, thus enhancing fungal growth. The
role of iron availability in the host–fungus inter-
action is underscored by the observations of
disseminated zygomycosis developing in patients
receiving iron chelation therapy, where the des-
ferroxamine molecule is subverted by the organ-
ism to serve as a siderophore.
Zygomycetes demonstrate a pattern of angio-
invasive tissue invasion that is similar to that of
Aspergillus spp. The resulting tissue infarction
produces clinically apparent eschars on physical
examination and necrotic tissue observed at
surgery.
Clinical manifestations. Zygomycosis in diabetic
patients presents classically as rhinocerebral
infection. Immunocompromised patients with
neutropenia or following transplantation may
present with either rhinocerebral or pulmonary
infection. Involvement of the ethmoidal sinuses
may be associated with concomitant cavernous
sinus thrombosis [122].
Diagnosis. Deﬁnitive diagnosis depends upon
demonstration of the characteristic hyphal mor-
phology in tissue. Culture of a zygomycete from
such tissue further deﬁnes the species. However,
cultures may prove to be negative in tissue that
clearly demonstrates hyphal elements. Such cul-
ture-negative results may be due to concurrent
antifungal chemotherapy or to loss of hyphal
viability in tissue homogenisation prior to culture.
Treatment and outcome. High doses of amphoteri-
cin B deoxycholate have been considered standard
therapy for treatment of localised or disseminated
zygomycosis. Lipid formulations of amphotericin
B, with or without the use of recombinant cytok-
ines, have been shown to have activity in patients
refractory to therapy with amphotericin B
deoxycholate [19,123]. Currently the available
triazoles, including voriconazole as well as the
echinocandins, are considered inactive as single
agents [124,125]. On the other hand, posaconazole
has activity in-vitro, in animal models, and in
some patients with refractory zygomycosis [126].
Further study of this promising triazole, as well
as newer approaches of combined drug and
immunotherapy, is warranted for this fungal
infection with a historically poor outcome.
Finally, surgical debridement is considered an
integral part of treatment for localised disease.
This may be in part the result of poor antifungal
activity for many isolates and of the inability of
the drug to penetrate necrotic tissues, particularly
in the paranasal sinuses.
Uncommon yeast pathogens
Trichosporon spp.
Microbiology. Trichosporon spp. are characterised
by hyphae, pseudohyphae, blastoconidia and
arthroconidia with varying morphological fea-
tures depending upon the species. All of the
various clinical manifestations were previously
ascribed to T. beigelii [127–129]. Recent revisions
of the taxonomic nomenclature based on differ-
ences in the morphology, biochemistry and
molecular genetics of isolates of the genus Tricho-
sporon have suggested that T. beigelli consists of 17
species with ﬁve varieties [130–135]. T. asahii and
T. mucoides are most commonly isolated in deep-
seated infections, T. cutaneum and T. asteroides
cause superﬁcial infection, and T. ovoides and
Walsh et al. Emerging and uncommon medically important fungal pathogens 57
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10 (Suppl. 1), 48–66
T. inkin are associated with white piedra. T. pullu-
lans and T. domesticum have also been reported to
cause systemic infection in immunocompromised
hosts. Most cases of invasive trichosporonosis,
heretofore attributed to T. beigelii, are considered
to be due to T. asahii.
Pathogenesis. The organism expresses glucuron-
oxylomannan (GXM) in its cell wall. GXM in
Trichopsoron is antigenically and biochemically
similar to that of GXM in C. neoformans [136–138].
Similar to C. neoformans, isolates of Trichosporon
from patients with fungemia have been shown to
express high concentrations of the GXM antigens
shown to inhibit phagocytosis by monocytes
[138]. Neutrophils and monocytes mediate the
phagocytic host response to Trichosporon. How-
ever, phagocytic host response may be attenuated
by GXM-mediated immunosuppression, resulting
in reduced phagocytosis and microbicidal activity
[139]. In-vitro studies with monocyte and gra-
nulocyte–monocyte colony-stimulating factor as
well as interferon-c have shown enhancement of
phagocytosis against Trichosporon, suggesting a
possible role for adjuvant immunotherapy with
recombinant cytokines, particularly GM-CSF.
The most common portals of entry are consid-
ered to be the gastrointestinal tract and vascular
catheters [140]. Bronchopneumonia has also been
seen, either because of inhalation of organisms
from the surrounding environment or secondary
to aspiration.
Epidemiology. Trichosporon spp. can cause life-
threatening fungemia and disseminated infection
similar to that caused by Candida spp. A common
cause of white piedra and summer-type hyper-
sensitivity in Japan, Trichosporon spp. also cause
fatal infections in immunocompromised patients,
most commonly those with leukaemia [127–
129,141], as well as in solid organ and haemato-
poietic stem cell transplant recipients [142–145].
The risk factors for infection include neutropenia,
corticosteroids and other factors of immunosup-
pression, as well as breaks in mucosal integrity
caused by surgery, placement of vascular cathe-
ters and cytotoxic chemotherapy leading to mu-
cositis and enteritis.
Clinical manifestations. Widespread trichosporo-
nosis can then occur by haematogenous dissem-
ination, leading to renal failure, pulmonary
inﬁltrates, multiple cutaneous lesions, chorioreti-
nitis and even septic shock. A chronic hepatic
trichosporonosis similar to chronic hepatic can-
didiasis has also been reported with Trichosporon
[127–129,146].
Treatment and outcome. Treatment relies on rapid
diagnosis and differentiation of Trichosporon from
the more common Candida spp. Although amph-
otericin B has been found to be inhibitory to
Trichosporon in vitro, it has poor fungicidal activity
with breakthrough infections seen in febrile neu-
tropenic patients on high-dose empiric treatment
with amphotericin B [147]. In a persistently
neutropenic rabbit model of disseminated trichos-
poronosis, treatment with amphotericin B deo-
xycholate (1 mg ⁄ kg per day) and a lipid
formulation of amphotericin B at 5 mg ⁄ kg per
day was unable to clear tissues in comparison
with saline-treated controls [140]. The mortality
associated with disseminated disease has been
reported as high as approximately 80% in immu-
nocompromised patients treated with amphoter-
icin B [127–129].
Antifungal triazoles have shown the best activ-
ity in-vitro and in animal models of disseminated
infection [140,148,149]. Fluconazole alone is con-
sidered the optimal ﬁrst-line therapy. A murine
model of disseminated trichosporonosis revealed
that the combination of ﬂuconazole with ampho-
tericin B may have enhanced clinical activity
against some isolates [150]. Echinocandins have
poor activity against Trichosporon in vitro and are
not recommended for therapy.
Blastoschizomyces capitatus
(formerly Trichosporon capitatum)
Microbiology. B. capitatus, previously known as
Trichosporon capitatum, was reclassiﬁed as a sep-
arate genus due to morphological, biochemical
and genetic differences. In comparison to Tricho-
sporon spp., B. capitatus develops anelloconidia
instead of arthroconidia.
Epidemiology. The risk factors for deep infection
by B. capitatus are similar to those of Trichosporon
spp.
Clinical manifestations. B. capitatus can dissemin-
ate haematogenously to multiple organ sites
including the liver, spleen, kidneys and bone in
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neutropenic patients. Blood cultures are usually
positive at the time of acute infection, and fungal
meningitis is more common than with dissemin-
ated candidiasis or trichosporonosis [151–159].
Cases of chronic disseminated infection have also
been seen.
Treatment and outcome. Similar to that of Tricho-
psoron spp., B. capitatus may have decreased
susceptibility to the fungicidal activity of amph-
otericin B and consequently poor clinical outcome
after treatment with amphotericin B in the setting
of neutropenia. Although ﬂuconazole and ﬂucyt-
osine appear to be more active in-vitro, break-
through infections have been reported in patients
on ﬂuconazole prophylaxis and resistant strains
have been reported as nosocomial pathogens
[158]. Optimal therapy remains to be deﬁned.
The combination of an azole antifungal and
amphotericin B with immunotherapy for initial
treatment may be the best approach for this
potentially life-threatening infection.
Malassezia spp.
Microbiology. Malassezia spp. are lipophilic yeasts,
which are part of the normal human cutaneous
commensal ﬂora. Malassezia spp. have been asso-
ciated with atopic dermatitis and seborrhoeic
dermatitis. Malassezia spp. are also considered
the aetiologic agents of tinea versicolor in the
immunocompetent patient. The genus Malassezia
has recently been revised to include seven species.
In a recent Canadian study the most common
isolates in patients with skin disease included
M. sympodialis, M. globosa and M. furfur [160–164].
Pathogenesis. Exposure of Malassezia to the lipid
emulsions in total parenteral nutrition solutions
enhances growth of this organism. This infection
has been well characterised in neonates, where
the organism causes fungemia and acute respir-
atory distress that corresponds to subendothelial
proliferation of the organisms amidst depositions
of lipid demonstrated histologically by neutral fat
stains [165,166]. Organisms are not usually found
in other deep tissues.
Epidemiology. In the immunocompromised pa-
tient,Malassezia has been noted to cause folliculitis
and catheter-related fungemia in the setting of
parenteral administration of lipids [167]. These
infections are not thought to be associated with
neutropenia. Most episodes of fungemia are
thought to be due to M. furfur. Malassezia is also a
well-recognized cause of canine, feline and equine
dermatitis and may lead to zoonosis. M. pachyder-
matis has been reported to be spread from dogs to
man via the hands of health-care workers, causing
infection in preterm neonates [168].
Clinical manifestations. Infection caused by Ma-
lassezia spp. may present as persistent fever,
fungemia, pulmonary inﬁltrates and thrombocy-
topenia. However, the organism seldom dissem-
inates to cause disease in other sites. Overall
outcome for this infection is more favourable than
infections with other uncommon fungi. One
should also note that isolated folliculitis in neu-
tropenic patients may simulate the lesions of
acute disseminated candidiasis. A direct smear of
these lesions, however, will demonstrate organ-
isms characteristic of M. furfur.
Diagnosis. Laboratory diagnosis is facilitated by
the addition of a lipid source such as olive oil.
Treatment and outcome. Malassezia spp. are usu-
ally susceptible to antifungal azoles but have
variable susceptibility to amphotericin B [169].
Virtually all cases of malassezia fungemia re-
spond to removal of the central venous catheter,
discontinuation of lipid parenteral nutrition,
with or without administration of antifungal
therapy. Management of malassezia fungemia
therefore includes the discontinuation of paren-
teral lipids, removal of the vascular catheter,
when possible, and administration of an anti-
fungal triazole.
Hansenula anomala
Microbiology. H. anomala is a member of the group
of ascomycetous yeasts. Also known as Pichia
anomala, this organism is a rare clinical entity that
has been reported with increasing frequency over
the past decade. In the majority of cases the
organism presents in its teleomorphic form and
less commonly in the anamorphic form of Candida
pelliculosa.
Epidemiology. Infection has been observed in chil-
dren and preterm neonates [170]. Other possible
risk factors include patients with acute leukaemia,
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use of broad-spectrum antibacterial agents, use of
central venous catheters, endotracheal intubation,
and high colonization rate with H. anomala [171].
Clinical manifestations. The spectrum of this dis-
ease ranges from asymptomatic fungemia to
severe disseminated life-threatening infection.
Fungemia is by far the most common presentation
of this infection.
Treatment and outcome. H. anomala is susceptible to
currently available antifungal agents, however,
two cases of breakthrough fungemia have been
described in patients receiving ﬂuconazole [172].
A recent outbreak of 24 cases of infection due toH.
anomala fungemia was reported in a cancer hospi-
tal in Brazil [171]. The median age was 11 years
and no deaths were attributed to the infection.
Another outbreak of H. anomala infection in eight
neonates was reported from a neonatal intensive-
care unit [146]; all cases but three had fungemia
and in three cases ventriculitis was demonstrated.
Patients were successfully treated with a combi-
nation of amphotericin B and 5-ﬂucytosine. Indi-
vidual cases have been described of endocarditis
in a previous intravenous drug user, of mediasti-
nal lymphadenitis in a patient with chronic
granulomatous disease, and of enteritis in a
paediatric patient. Response rate due toH. anomala
fungemia is high when therapy is instituted early
and the intravascular catheter is removed.
Endemic dimorphic fungi: focus on Penicillium
marneffei
Immunocompromised patients may travel to or
from areas endemic for pathogenic dimorphic
fungi such as Histoplasma capsulatum, Coccidioides
immitis, Blastomyces dermatitidis, Paracoccidioides
brasiliensis or Penicillium marneffei. In this section
on endemic dimorphic fungi, we will focus on
P. marneffei as an emerging pathogen.
Microbiology. Most Penicillium species are consid-
ered saprophytes and common laboratory con-
taminants. P. marneffei is a facultative intracellular
pathogen and the only known thermally dimor-
phic fungus of the genus Penicillium. At room
temperature, P. marneffei exhibits the characteris-
tic morphology of the genus; in contrast, it grows
as a yeast that replicates by ﬁssion with a
characteristic septum when found in infected
tissue or at 37 C.
Pathogenesis. The mode of transmission is not
well understood but is probably via ingestion
or inhalation of the fungus. The conidia of
P. marneffei present in the environment are appar-
ently inhaled and undergo conversion to an
elongated yeast-like form. Pulmonary alveolar
macrophages appear to be the primary host
defence against Penicillium. Alveolar macrophag-
es and mononuclear cells may be replete with
multiple yeast forms. Profound T-cell-mediated
immunity impairment as a result of HIV infection
accounts for the abnormal regulation of pulmon-
ary alveolar macrophages. Three types of histo-
pathological reactions have been described with
P. marneffei infections: granulomatous, suppura-
tive and necrotising. The ﬁrst two reactions have
been noted in persons with normal immunity,
whereas the necrotising reaction was associated
with penicillosis in immunocompromised pa-
tients.
Epidemiology. P. marneffei has emerged as an
important fungal pathogen that causes dissemin-
ated infection in HIV-infected patients residing in
or travelling to South-east Asia where the disease
is endemic [173–177]. P. marneffei constitutes the
third most common opportunistic infection in
HIV-infected patients in certain parts of South-
east Asia and is endemic in the Guangxi province
of China, Hong Kong and Taiwan. The incidence
of penicillosis has increased signiﬁcantly for the
past few years, paralleling the incidence of HIV
infection, from 30 cases before 1990 to more than
160 by the end of 1995. Although penicillosis is
most commonly seen in adults infected with HIV,
the disease has also been detected in children and
adults without immunodeﬁciency. Bamboo rats
(Rhyzomys sumatrensis, R. pruinosis, R. sinensis and
Cannomyus badius) were implicated in the epi-
demiology of penicilliosis, but their relationship
to human disease is not clear.
Clinical manifestations. In a series of 80 patients
reported by Supparatpinyo et al. [175] the most
common presentation was low-grade fever, anae-
mia, weight loss and one or multiple skin lesions.
Characteristically, most lesions had a central
umbilication reminiscent of molluscum contagio-
sum. Palatal and pharyngeal lesions were also
seen. Fungemia, cough and lymphadenopathy
were present in 50% of the cases. Pulmonary
lesions can appear as reticulonodular or diffuse
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alveolar inﬁltrate, however cavitary lesions and
haemoptysis were also described. The average
number of CD4+ T lymphocytes at presentation
was 64 cells ⁄mm3. Gastrointestinal involvement
by P. marneffei ranges from oesophagus to colon,
and mucosal lesions appear as shallow ulcers
indistinguishable from those of intestinal histo-
plasmosis.
Diagnosis. Diagnosis of penicilliosis is usually
made by identiﬁcation of the organism from
smear, culture or histopathological sections. Ra-
pid diagnosis of presumed infection could be
obtained by microscopic examination of bone
marrow aspirate, lymph node, or skin biopsy
smear. Microscopic examination reveals yeast
forms both within phagocytes and extracellularly.
This organism may appear morphologically sim-
ilar to Histoplasma capsulatum when found intra-
cellularly [174]. In the extracellular environment
in-vivo, the fungal cell elongates, becomes slightly
curved, and forms an intercellular septum. The
demonstration of characteristic central septation
and elongated sausage-shaped forms, by methen-
amine silver stain, clearly distinguish P. marneffei
from H. capsulatum.
Treatment and outcome. P. marneffei is usually
susceptible to both amphotericin B and the anti-
fungal azoles [178]. Treatment with amphotericin
B has been successful in the majority of cases.
Fluconazole and itraconazole should also be
considered for mild to moderate cases of penicil-
losis. In a recent nonrandomized study in HIV-
infected patients with disseminated P. marneffei
infection [173], a high response (97%) rate was
achieved with a regimen of amphotericin B
(0.6 mg ⁄ kg ⁄day) for 2 weeks, followed by oral
itraconazole (400 mg ⁄day) for 10 weeks. This
regimen was effective and allowed a shortened
hospital stay.
Relapse is common 6 months after discontinu-
ation of therapy. A recent double-blind trial of
secondary prophylaxis with itraconazole versus
placebo in HIV patients with penicillosis demon-
strated that none of the patients treated with
itraconazole had relapsed, compared with 57% in
the placebo arm [178]. Based on these data, life-
long suppressive therapy with itraconazole is
recommended in HIV-patients with penicillosis.
The impact of HAART on the management and
outcome of penicilliosis has not been adequately
assessed to permit a recommendation for discon-
tinuation.
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